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ABSTRACT  42 
ARCTIC was a multi-center, randomized-controlled, open, phase IIB non-inferiority trial in 43 
previously untreated Chronic Lymphocytic Leukemia (CLL). Conventional frontline therapy in fit 44 
patients is fludarabine, cyclophosphamide and rituximab (FCR). The trial hypothesized that 45 
including mitoxantrone with low-dose rituximab (FCM-miniR) would be non-inferior to FCR. 200 46 
patients were recruited to assess the primary endpoint of complete remission (CR) rates according 47 
to IWCLL criteria. Secondary endpoints were progression-free survival (PFS), overall survival 48 
(OS), overall response rate, minimal residual disease (MRD) negativity, safety and cost-49 
effectiveness. The trial closed at the pre-planned interim analysis. At final analysis, CR rates were 50 
76% FCR vs. 55% FCM-miniR [adjusted odds-ratio: 0.37; 95% CI: 0.19-0.73]. MRD-negativity 51 
rates were 54% FCR vs. 44% FCM-miniR. More participants experienced Serious Adverse 52 
Reactions with FCM-miniR (49%) compared to FCR (41%). There are no significant differences 53 
between the treatment groups for PFS and OS. FCM-miniR is not expected to be cost-effective 54 
over a lifetime horizon. In summary, FCM-miniR is less well tolerated than FCR with an inferior 55 
response and MRD-negativity rate and increased toxicity, and will not be taken forward into a 56 
confirmatory trial. The trial demonstrated that oral FCR yields high response rates compared to 57 
historical series with intravenous chemotherapy. 58 
 59 
 60 
 61 
 62 
 63 
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INTRODUCTION 64 
Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder accounting for 30% of 65 
adult leukaemia and 25% of Non-Hodgkin Lymphoma. It is the most common leukemia above the 66 
age of 50 years with a median age of diagnosis of 70 years. The treatment of CLL is tailored around 67 
the physical state of the patient due to toxicity associated with the chemotherapy based treatments. 68 
CLL is still an incurable disease, and most patients will eventually become resistant to treatment.  69 
For physically fit patients, the addition of rituximab (MabThera) to fludarabine and 70 
cyclophosphamide (FCR) has become the standard of care based on evidence from large 71 
randomized controlled trials(1, 2). However, the dose of rituximab has not been established 72 
systematically in CLL or in combination with chemotherapy. Rituximab monotherapy at a dose of 73 
375mg/m2 induced an overall response rate (ORR) of 13% in previously-treated CLL/small 74 
lymphocytic lymphoma (SLL)(3, 4). Thrice weekly rituximab (375mg/m2) and higher weekly 75 
doses of rituximab (0.5-2.5g/m2) in previously untreated patients induced a modest ORR of 43% 76 
and 40%, respectively(5-7). The poor response was thought to be due to low CD20 expression on 77 
CLL cells and rituximab binding to CD20 positive cellular debris. The loss of CD20 antigen from 78 
&//FHOOVZKHQH[SRVHGWRULWX[LPDEWHUPHG³DQWLJHQshaving´ is well described in CLL. Most 79 
of the CLL cells were cleared after 30mg of rituximab followed by recrudescence of CLL cells 80 
which have lost >90% of CD20 expression. Low-dose rituximab thrice weekly at 20-60mg/m2 may 81 
promote enhanced clearance of CLL cells by preserving CD20 expression(8). Subcutaneous 82 
rituximab thrice weekly at a dose of 20mg resulted in reduction of CD20 expression on CLL cells 83 
but sufficient expression was maintained during the course of 6-12 weeks in another study(9). 84 
Thrice weekly rituximab at 20mg/m2 in combination with Alemtuzumab and Pentostatin showed 85 
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that this dose is able to opsonize and clear the majority of circulating cells, but the loss of CD20 86 
is less pronounced(10). Hence, rituximab at doses of 20mg/m2 can be effective in CLL.  87 
The combination of mitoxantrone with fludarabine and cyclophosphamide (FCM) is reported in 88 
60 relapsed or resistant patients with CLL(11) to yield a 78% ORR, with 50% of patients achieving 89 
a complete remission (CR) and 10 patients Minimal Residual Disease (MRD) negativity. A non-90 
randomized Phase II trial of FCM plus rituximab (FCM-R)(12) reported 82% CRs and 93% ORR 91 
in previously untreated CLL, with 46% achieving MRD-negativity. The NCRI randomized Phase 92 
II study including FCM and FCM-R in 52 previously-treated CLL patients reported CRs of 65% 93 
(FCM-R) versus 58% (FCM), with MRD-negativity in 5 patients (FCM-R) and 3 patients 94 
(FCM)(13).  95 
The aim of the ARCTIC (Attenuated dose Rituximab with ChemoTherapy In CLL) trial was to 96 
test the hypothesis that a low-dose of rituximab (100mg per cycle) in combination with FCM 97 
(FCM-miniR) would be as effective as standard of care (FCR). It is hypothesized that FCM-miniR 98 
may result in effective tumor clearance and preservation of CD20 expression on CLL cells.  99 
The cost-effectiveness of delivering FCM-miniR as an alternative to the standard therapy FCR is 100 
also critical. Six cycles of rituximab at a dose of 500mg/m2 are time consuming to give and 101 
expensive compared to low doses (100mg per cycle). The non-inferiority design of the trial helps 102 
to establish whether lowering the dose of rituximab and hence reducing the cost of treatment 103 
impacts on the efficacy in terms of CR rates, as well as the longer-term progression-free survival 104 
(PFS) and overall survival (OS) outcomes.  105 
 106 
PATIENTS AND METHODS 107 
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Trial Design 108 
ARCTIC was a multi-center, randomized, controlled, open-label, phase IIB non-inferiority trial 109 
including patients with previously-untreated CLL who required treatment by IWCLL criteria(14). 110 
Patients were randomized via a central computer-generated minimization programme 111 
incorporating a random element 1:1 to FCR or FCM-miniR. Randomization was stratified to 112 
ensure balance for center, Binet Stage (Progressive A or B, C), age group DQGsex. 113 
The primary objective was to assess whether FCM-miniR was non-inferior to FCR in terms of CR 114 
rates, including CR with incomplete marrow recovery (CRi), in patients with previously untreated 115 
CLL. The results would be used to determine whether FCM-miniR should be taken forward into a 116 
larger definitive Phase III trial. 117 
An independent Data Monitoring Committee (DMC) was established to review the safety and 118 
ethics of the trial. The DMC reviewed unblinded safety data on a six-monthly basis and unblinded 119 
safety and trial progress reports on an annual basis. There was a pre-planned interim assessment 120 
of efficacy on half the required number of participants. The DMC reported to an established trial 121 
steering committee (TSC) that provided general oversight for the trial. 122 
The trial was approved by relevant institutional ethical committees and regulatory review bodies. 123 
The trial was registered as an International Standard Randomized Controlled Trial 124 
(ISRCTN16544962) and on the European Clinical Trials Database (EudraCT: 2009-010998-20). 125 
Patients 126 
The intention was to recruit 206 patients from hospitals around the United Kingdom (UK). Eligible 127 
participants had progressive CLL requiring treatment by IWCLL criteria(14); no prior treatment 128 
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for CLL; WHO performance status 0-2; Binet Stage progressive A, B or C; and had provided 129 
written consent. Patients were not eligible if they had Hepatitis B or C; an active secondary 130 
malignancy (excluding basal cell carcinoma of the skin); an active infection or a past history of 131 
anaphylaxis following exposure to rat or mouse-derived complementarity determining region 132 
(CDR)-grafted humanized monoclonal antibody. Patients with creatinine clearance greater than 133 
30ml/min were allowed to enter the trial with guidance on dose reduction for fludarabine. Patients 134 
with a 17p-deletion were eligible for enrollment due to lack of treatment options at the time of 135 
designing the trial.  Participants were able to withdraw from the trial at any time. 136 
Treatment and Assessments 137 
Treatment with FCR or FCM-miniR was repeated every 28 days for a total of six cycles. 138 
Fludarabine and cyclophosphamide were administered orally at doses of 24mg/m2/day and 139 
150mg/m2/day respectively for the first five days of each cycle. These doses are pharmacologically 140 
equivalent to the doses used when FCR is given intravenously for CLL(15). Full dose rituximab 141 
was administered intravenously at 375mg/m2 on day 1 of cycle 1 and 500mg/m2 in cycles 2-6. In 142 
participants with lymphocyte counts greater than 25x109/L, the dose of rituximab was split to 143 
100mg on day 1 with remaining rituximab given on day 2 to reduce the risk of infusion related 144 
reactions. Participants unable to tolerate oral chemotherapy were permitted to receive equivalent 145 
intravenous doses of fludarabine (25mg/m2/day for 3 days) and cyclophosphamide (250mg/m2/day 146 
for 3 days). FCM-miniR included intravenous mitoxantrone (6mg/m2/day) and 100mg rituximab 147 
on day 1 of each cycle. All participants were given allopurinol at least in cycle 1. Prophylaxis for 148 
pneumocystis carinii pneumonia (PCP) and aciclovir were given throughout the treatment. 149 
Secondary prophylaxis with granulocyte-colony stimulating factor (G-CSF) (lenograstim 150 
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263mcg/day; days 7-13) was recommended for scheduled delays of therapy due to neutropenia. 151 
Appropriate dose reductions were recommended in participants with therapy-related cytopenias. 152 
Participants were assessed for response to treatment at 3 months post-treatment, 12, 18 and 24 153 
months post-randomization or until disease progression requiring treatment. Long-term annual 154 
follow-up for survival is performed until death. 155 
Endpoints 156 
The primary endpoint was CR rate (including CRi) at 3 months post-treatment. Response was 157 
centrally assessed according to the IWCLL criteria(14) by two independent, experienced CLL 158 
haematologists blinded to treatment allocation. An independent arbiter reviewed discordant 159 
reports.  160 
Secondary endpoints at 3 months post-treatment included MRD negativity, assessed in the bone 161 
marrow by highly sensitive multi-parameter flow cytometry with a level of detection below 1 CLL 162 
cell in 10 000 leukocytes(16, 17); ORR defined as at least a partial remission (PR); and safety and 163 
toxicity as graded by CTCAE V3.0(18). 164 
Longer-term secondary endpoints included PFS, OS, time to MRD relapse in participants who 165 
became MRD-negative, and cost-effectiveness.  166 
Sample size 167 
Previous studies showed FCR CR rates of at least 50%(19, 20). With 80% power to show non-168 
inferiority, where this is defined as FCM-miniR being not more than 10% worse in terms of CR 169 
rates than FCR, an assumed 10% difference in favor of FCM-miniR, a 1-sided significance level 170 
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(Į) of 2.5%(21) and 80% power, 98 patients were required per group. 206 patients were planned, 171 
allowing for 5% dropout.   172 
A formal interim analysis to allow large differences between the treatment groups to be reported 173 
early was planned on the short-term efficacy data on half the required participants (n=103). A 174 
stringent significance level was required for the interim analysis (0.005, 2-sided) using the 175 
2¶%ULHQ-Fleming(22) alpha-spending function. 176 
Statistical Methods 177 
All analyses were conducted on the intention-to-treat (ITT) population, in which participants were 178 
included according to their randomized treatment. A per-protocol analysis was planned for the 179 
primary endpoint, including participants who received at least one cycle of treatment as 180 
protocolled and were not major eligibility violators. Safety analyses included participants 181 
according to the treatment they actually received. 182 
Methods for handling missing endpoint data were pre-specified and approved by the Chief 183 
Investigator. Participants with a missing assessment who died from CLL or treatment-related 184 
toxicity prior to their primary endpoint assessment, or discontinued treatment early due to non-185 
response or toxicity were treated as non-responders/MRD-positive. In the formal statistical 186 
analysis of the primary endpoint, for participants with at least a PR but missing trephine data to 187 
confirm a CR, imputation methods treated MRD-negative participants as having a CR and MRD-188 
positive as not. Participants without an available endpoint assessment were not included in the 189 
formal statistical analysis of the primary endpoint. This was appropriate as it can be assumed that 190 
data are missing completely at random (MCAR), since assessments were most likely unavailable 191 
due to samples being un-assessable or missed in error, rather than participant refusal due to level 192 
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of response or treatment allocation. Sensitivity analyses assessed the robustness of the assumptions 193 
regarding missing primary endpoint data.  194 
Binary logistic regression models compared CR rates, proportions with undetectable MRD and ORR 195 
between the treatment groups, adjusting for the minimization factors, excluding center. The 196 
differences in proportions are reported with 95% confidence intervals (CIs). The lower limit of the 197 
CI for the CR rates was compared with the non-inferiority margin of 10%, expressed as an odds 198 
ratio (OR). 199 
Kaplan-Meier curves are presented for the PFS and OS endpoints. Cox regression analysis 200 
formally compared time to MRD relapse, PFS and OS. Participants without evidence of an event 201 
at the time of analysis were censored at the last date they were known to be alive and event-free.  202 
Safety analyses summarized the number of safety events occurring after randomization including 203 
treatment-related mortalities and incidence of secondary cancers.  204 
Pre-specified exploratory subgroup analyses assessed the heterogeneity of the treatment effect 205 
among subgroups of interest for the primary endpoint, PFS and OS. Formal statistical testing 206 
between subgroups was not appropriate due to multiple testing errors and the reduced numbers in 207 
each subgroup.  208 
An economic evaluation was conducted from a National Health Service (NHS) and Personal Social 209 
Services (PSS) perspective, with health benefit measured in Quality-Adjusted Life-Years 210 
(QALYs), using patient-reported EQ-5D-3L questionnaires(23). A within-trial analysis compared 211 
the outcomes and costs over 24 months using individual patient data from the trial, and a modified 212 
Markov model was used to estimate lifetime cost-effectiveness. The model included three health 213 
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states: disease free, recurrence and death. Results are reported in 2013 GBP (£), and for 214 
information costs are presented in US Dollars ($) using an exchange rate of 1:1.43.  215 
 216 
RESULTS 217 
Recruitment and Early Closure 218 
Two-hundred participants were recruited between December 2009 and September 2012 (FCR: 219 
100, FCM-miniR: 100) from 34 UK institutions with local ethical and management approval. At 220 
the time of reporting, it has been approximately 6 years since the trial opened to recruitment, with 221 
a median follow-up of just over 4 years. 222 
The CONSORT diagram (Figure 1) shows the flow of participants throughout the trial.  223 
The trial closed early in September 2012 following recommendation from the DMC and TSC. At 224 
the pre-planned interim analysis on 103 participants, 72 (69.9%) received 6 cycles of treatment 225 
[FCR: 38/51 (74.5%), FCM-miniR: 34/52 (65.4%)], and 61 (59.2%) achieved a CR [FCR: 34/51 226 
(66.7%), FCM-miniR: 27/52 (51.9%)]. Of the participants with an assessable response, 61/85 227 
(71.8%) achieved a CR [FCR: 34/41 (82.9%), FCM-miniR: 27/44 (61.4%)], with a difference in 228 
response rates (FCM-miniR ± FCR) of -21.6% (99.5%CI: -48.0%, 4.8%), adjusted p=0.037. 229 
Although not significant at the pre-planned interim level Į , the results approached 230 
significance in favor of FCR. There was also evidence of additional toxicity in the FCM-miniR 231 
group with 65.4% (34/52) of participants experiencing a Serious Adverse Event (SAE) compared 232 
to 51.0% (26/51) with FCR. The DMC recommended ceasing recruitment immediately; the 23 233 
participants still receiving FCM-miniR were recommended to transfer to FCR for the remainder 234 
of their treatment cycles. Twenty-one FCM-miniR participants transferred to receive treatment 235 
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with FCR (labelled FCM-miniR/FCR) following discussion with their treating clinician, two 236 
participants elected to continue to receive FCM-miniR for their remaining treatment cycles. 237 
Patient Characteristics 238 
Baseline characteristics are displayed in Table 1. The median age was 63 years (range 36±80) with 239 
75 participants (37.5%) aged >65 years. There was a male predominance [135 (67.5%)], and 34 240 
participants (17.0%) were Binet Stage progressive A, 95 (47.5%) stage B and 71 (35.5%) stage C. 241 
A majority of participants [116 (58.0%)] were WHO performance status (PS) 0, with 77 (38.5%) 242 
PS 1 and 7 (3.5%) PS 2.  Overall, 103 participants (51.5%) had B-symptoms, a higher proportion 243 
with FCM-miniR [FCR: 46 (46.0%), FCM-miniR: 57 (57.0%)] whilst 115 (57.5%) had a ȕ-244 
microglobulin concentration of mg/L, and 31 (15.5%) creatinine clearance levels of 30-245 
60mls/min. Of the evaluable participants, 7/183 (3.8%) had a 17p-deletion [FCR: 4 (4.3%), FCM-246 
miniR: 3 (3.3%)]; 30/188 (16.0%) an 11q-deletion [FCR: 10 (10.8%), FCM-miniR: 20 (21.1%)].  247 
104/165 participants (63.0%) ZHUHFRQVLGHUHGWREHµSRRUer ULVN¶ [FCR: 52 (63.4%), FCM-miniR: 248 
52 (62.7%)], in terms of VH mutational status i.e. VH unmutated or involving the VH3-21 gene.  249 
Treatment 250 
Of the 200 participants, 141 (70.5%) received 6 cycles of treatment [FCR: 70 (70.0%), FCM-251 
miniR: 51 (64.5%), FCM-miniR/FCR: 20 (95.2%)] and 31 (15.5%) received  cycles of treatment 252 
[FCR: 15 (15.0%), FCM-miniR: 16 (20.3%), FCM-miniR/FCR: 0 (0.0%)] (Table 2). Two FCR 253 
participants did not receive any trial treatment, one had received prior therapy for CLL, and the 254 
other had a 17p deletion and was withdrawn from the trial, patient and clinician decision (Figure 255 
1). Overall, 59 participants (29.5%) discontinued treatment prematurely [FCR: 30 (30.0%), FCM-256 
miniR: 28 (35.4%), FCM-miniR/FCR: 1 (4.8%)]. Reasons included: toxicity (n=44); progressive 257 
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disease (n=3); stable disease with no or minimal response (n=3); ineligibility (n=1), patient 258 
decision (n=3); clinician decision (n=4); other (n=1). A total of 94 participants (47.0%) received 259 
G-CSF during treatment as recommended in the protocol as secondary prophylaxis, with a higher 260 
proportion in the FCM-miniR group [FCR: 42 (42.0%), FCM-miniR: 40 (50.6%)] (Table 2). 261 
Thirteen participants unable to tolerate oral chemotherapy received equivalent intravenous doses 262 
[FCR: 7 (7.0%), FCM-miniR: 5 (6.3%), FCM-miniR/FCR: 1 (4.8%)]. 263 
Efficacy 264 
Of the 200 participants, 124 (62.0%) achieved a CR [FCR: 68 (68.0%), FCM-miniR: 39 (49.4%), 265 
FCM-miniR/FCR: 17 (81.0%)].   In the formal analysis of the primary endpoint including 266 
imputation based on MRD outcome, 111/167 (66.5%) achieved a CR, [FCR: 70/92 (76.1%), FCM-267 
miniR: 41/75 (54.7%)]. The difference in response rates (FCM-miniR ± FCR) was -21.4% in favor 268 
of FCR (95%CI: -35.8%, -7.0%). In the logistic regression analysis, the OR for achieving a CR 269 
with FCM-miniR compared to FCR was 0.37 (95%CI: 0.19, 0.73) (Table 3). A 10% non-inferiority 270 
reduction from the FCR CR rate gives an OR limit of 0.61. Since the lower limit, and in fact the 271 
mean of the 95% CI for the treatment effect is less than 0.61, and the upper limit is below 1, there 272 
is evidence that FCM-miniR is significantly inferior to FCR. The per-protocol analysis (n=166) 273 
concurred with the outcome of the ITT analysis, OR=0.38 (95%CI: 0.19, 0.75). The sensitivity 274 
analyses did not alter the findings.  275 
There were no large differences in proportions achieving a CR by sex [Males: 76/117 (65.0%), 276 
Females: 35/50 (70.0%)], age group [ 75/106 (70.8%), >65: 36/61 (59.0%)], or Binet stage [A 277 
progressive/B: 76/111 (68.5%), C: 35/56 (62.5%)]. A significantly higher proportion of 278 
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participants who received >3cycles of treatment achieved a CR [F\FOHV 7/25 (28.0%), >3cycles: 279 
104/142 (73.2%)], with difference [-45.2% (95%CI: -64.3%, -26.2%)]. 280 
All assessable participants with a 17p deletion failed to achieve a CR (n=6). Lower proportions of 281 
participants with an 11q deletion and µpoorer risk¶ VH mutational status achieved a CR [11qdel: 282 
14/24 (58.3%), no 11qdel: 90/133 (67.7%)], [VH unmutated or VH3-21: 54/87 (62.1%), VH 283 
mutated: 36/52 (69.2%)]. 284 
Of the 200 participants, 184 (92.0%) achieved at least a PR [FCR: 94 (94.0%), FCM-miniR: 69 285 
(87.3%), FCM-miniR/FCR: 21 (100%)]. Of the assessable participants, the ORR was 92.6% 286 
(163/176) with a higher proportion in the FCR group than FCM-miniR [FCR: 94/98 (95.9%), 287 
FCM-miniR: 69/78 (88.5%), with a difference (FCM-miniR±FCR) of -7.5% (95%CI: -15.6%, 288 
0.6%). A binary logistic regression analysis was unable to be performed due to the small number 289 
of participants in the non-responders group. 290 
Of the 200 participants, 85 (42.5%) achieved MRD negativity assessed in the bone marrow three-291 
months post-therapy [FCR: 45 (45.0%), FCM-miniR: 29 (36.7%), FCM-miniR/FCR: 11 (52.4%)].  292 
In the formal analysis of MRD (excluding FCM-miniR/FCR participants and those with a missing 293 
MRD assessment) 74/149 (49.7%) achieved MRD negativity [FCR: 45 (54.2%), FCM-miniR: 29 294 
(43.9%)].  There was a non-significant trend towards FCM-miniR resulting in lower MRD-295 
negativity rates at three months with a difference (FCM-miniR ± FCR) of  -10.3% (95%CI: -26.3%, 296 
5.8%), adjusted OR: 0.65 (95%CI:0.33, 1.26)] (Table 3).  297 
 At the time of analysis (3-years post-randomization of the final participant), 33 (16.5%) 298 
participants have died [FCR: 14 (14.0%), FCM-miniR: 18 (22.8%), FCM-miniR/FCR: 1 (4.8%)] 299 
and 73 (36.5%) have either progressed or died [FCR: 34 (34.0%), FCM-miniR: 35 (44.3%), FCM-300 
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miniR/FCR: 4 (19.0%)]. Figure 2 presents the PFS and OS Kaplan-Meier curves by treatment 301 
group (excluding FCM-miniR/FCR participants). At 36 months post-randomization, the PFS rate 302 
is FCR: 75.3% vs. FCM-miniR: 71.3%; with OS rate FCR: 89.1%, FCM-miniR: 84.3%.  The 303 
hazard ratios (HR) were not significant in the adjusted Cox regression model [PFS: HR=1.29, 304 
95%CI:(0.80, 2.07), p=0.298; OS: HR=1.62, 95%CI:(0.80, 3.28), p=0.178].  305 
Of the 85 participants who were MRD-negative in the bone marrow at three months post-treatment 306 
(Table 3), 9 (10.6%) were reported to have relapsed at the MRD level in the peripheral blood or 307 
progressed [FCR: 5/45 (11.1%), FCM-miniR: 4/29 (13.8%)] at the end of the planned two-year 308 
follow-up. The curves are not presented due to the small number of events. 309 
For the planned subgroup analyses, Kaplan-Meier curves demonstrated an improved PFS in 310 
participants who achieved a CR or MRD negativity at 3 months post-treatment (Figure 3). There 311 
was a trend towards participants with a VH mutated gene (and not VH3- LH µVWDQGDUG ULVN¶312 
patients showing an improved PFS over those with µpoor risk¶ (Figure3). Subgroup analyses for 313 
OS show similar trends.  314 
Economic Evaluation 315 
Over the planned 24-month trial period, FCM-miniR produced a mean cost saving of £6 619 [$9 316 
649] (s.d.£1 061 [$1 518]), and QALY loss of -0.059(s.d.0.06) compared to FCR. Assuming that 317 
one QALY is valued at £20 000, as per UK standard, FCM-miniR is cost-effective over the trial 318 
period, producing a positive incremental net health benefit (+0.27 QALYs; s.d.0.08) due to the 319 
short-term cost savings associated with FCM-miniR treatment. However, FCM-miniR is not 320 
expected to be cost-effective over a lifetime horizon, with an expected lifetime cost-saving of £7 321 
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723 [$11 048] (s.d. £3 281 [$4 694]), and QALY loss of -0.73(s.d.0.42), resulting in an incremental 322 
net health loss (QALY: -0.34; s.d.0.40) (Table 4).  323 
Safety and Toxicity 324 
The safety population included 198 participants (Figure 1). 183 SAEs were reported from 104 325 
(52.5%) participants, from a lower proportion receiving FCR (49.0%) compared to FCM-miniR 326 
(58.2%).  145 Serious Adverse Reactions (SARs) were reported from 89 (44.9%) participants 327 
[FCR: 62 events from 41 (41.0%); FCM-miniR: 67 events from 39 (49.4%); FCM-miniR/FCR: 16 328 
events from 9 (47.4%)]. The most commonly reported SARs, 62.1% of events (n=90), were 329 
infections and infestations (Table 5). Ninety-six (48.5%) participants required hospitalization for 330 
an SAE with similar proportions in each treatment group (Table 5).  331 
One Suspected Unexpected Serious Adverse Reaction (SUSAR) was reported from a participant 332 
receiving FCR. A squamous cell carcinoma, two lesions on the lower back and central chest was 333 
diagnosed approximately 4 months after the participant received 6 cycles of treatment.  334 
Non-serious adverse events (AE) were reported from 192 (97.0%) participants with similar 335 
proportions in each treatment group. Of the 2163 AEs reported, 388 (17.9%) were graded as 336 
CTCAE grade 3 or above [FCR: 168 (15.0%); FCM-miniR: 193 (22.4%); FCM-miniR/FCR: 27 337 
(14.8%)] (Table 5).  338 
There were no treatment-related mortalities reported within 3 months of the end of protocol 339 
treatment.  340 
Within 4 years following treatment, 26 participants (13.1%) had been diagnosed with a second 341 
cancer [FCR: 13 (13.0%); FCM-miniR: 12 (15.2%); FCM-miniR/FCR: 1 (5.3%)]. The most 342 
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commonly reported secondary cancers were non-melanoma skin cancers in 5.1% (n=10) of 343 
participants, followed by hematological cancers (AML/MDS) in 3.0% of participants (n=6) (Table 344 
5).  345 
 346 
DISCUSSION 347 
Participants randomised to FCM-miniR had a significantly lower CR rate than those randomised 348 
to FCR (54.7% vs. 76.1%), indicating that FCR is the more effective treatment. This seems, at 349 
least in part, due to the higher toxicity associated with the addition of mitoxantrone to FCR with 350 
41.1% of participants receiving FCR reporting a SAR compared with 49.4% receiving FCM-351 
miniR. Key secondary endpoints were consistent in demonstrating that FCR has greater efficacy, 352 
with a higher proportion of participants achieving MRD negativity (FCR: 54.2%, FCM-miniR: 353 
43.9%). Trial follow-up is still relatively immature (median 4 years), and there are a high number 354 
of censored observations, but to date the PFS and OS are favorable compared to previous studies. 355 
There are no significant differences between the treatment groups for PFS and OS.  356 
The cost-effectiveness analysis indicates that whilst FCM-miniR is expected to be cost-effective 357 
in the short term, it is unlikely to be cost-effective when taking into account long-term costs and 358 
health benefits, although there is significant uncertainty around the long-term results.  359 
The design of this trial and its companion trial, ADMIRE comparing FCR with FCM-R (reported 360 
in the companion paper), were based on several non-randomised Phase II trials suggesting that the 361 
addition of mitoxantrone to FCR improved outcomes in CLL. The lower dose of rituximab was 362 
based on pre-clinical and biological responses seen in small studies examining the impact of lower 363 
doses of rituximab as a single agent in CLL. Both trials failed to demonstrate the expected 364 
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improvement in outcome for the proposed interventions. The use of randomised Phase II trials 365 
allows a more critical assessment of the value of any proposed changes to treatment giving a more 366 
robust assessment prior to launching prolonged and expensive Phase III trials. Given the rapidly 367 
changing therapy in diseases such as CLL, the use of randomised Phase II trials either as stand-368 
alone trials or as part of seamless Phase II/III designs is an efficient way to prioritise appropriate 369 
Phase III trial design and is highly recommended compared to large non-comparative Phase II 370 
trials that are commonly performed. 371 
In addition the outcomes for both the ARCTIC and ADMIRE trials are consistent with each other 372 
and demonstrate that the delivery of fludarabine and cyclophosphamide by the oral route in FCR 373 
is at least as effective as, and possibly more effective than, FCR when the chemotherapy 374 
component is given intravenously. Oral FCR is also much more convenient for patients and results 375 
in less use of valuable medical resources as patients only require a single day case visit per cycle 376 
of treatment rather than three that is required if FCR is given intravenously. 377 
In summary, we demonstrate that FCM-miniR is not non-inferior to FCR in terms of the primary 378 
endpoint of CR at 3-months post-treatment. In addition, FCM-miniR shows evidence of reduced 379 
efficacy in terms of MRD and survival, had increased toxicity, and is not cost-effective longer 380 
term. In view of this, FCM-miniR will not be taken forward into a larger definitive Phase III trial.  381 
The trial demonstrated that oral FCR yields extremely high response and MRD negativity rates 382 
compared to historical series in which the chemotherapy was given intravenously, and remains the 383 
gold-standard therapy for CLL in participants considered fit for fludarabine-based therapy. We 384 
also demonstrate the value of randomised Phase II trials to improve the quality of future Phase III 385 
trials. 386 
 387 
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FIGURES AND TABLES 501 
Figure 1 CONSORT Diagram 502 
  503 
Analysis populations: 
Intention-to-treat (n=92): 
- Excluded from ITT analysis (n=8): 
o Missing primary endpoint data (n=8) 
 
Per-protocol (n=91): 
- Excluded from PP analysis (n=9): 
o Missing primary endpoint data (n=8a) 
o Did not receive any FCR (n=1a) 
o Breach of eligibility criteria (prior therapy for CLL) and did not 
receive any FCR (n=1) 
 
Safety population (n=100): 
- Excludes 2 FCR participants who failed to receive any treatment 
- Includes 2 FCM-miniR participants who received FCR from cycle 1 
 
a One participant did not receive any FCR and also had missing primary 
endpoint data and is therefore recorded twice 
 
Analysis populations: 
Intention-to-treat (n=75): 
- Excluded from ITT analysis (n=25): 
o Missing primary endpoint data (n=5b) 
o Received FCR (n=21b) 
 
 Per-protocol (n=75): 
- Excluded from PP analysis (n=25): 
o Missing primary endpoint data (n=5b) 
o Received FCR (n=21b) 
 
 
Safety population (n=98): 
- FCM-miniR (n=79) 
- FCM-miniR/FCR (n=19) 
b One participant received FCR and had missing primary endpoint data 
and is therefore recorded twice 
Assessed for eligibility (n=548) 
Excluded (n=348) 
- Patient clinically ineligible (n=228) 
- Patient did not wish to participate (n=39) 
- Patient too ill to participate (n=4) 
- Other reason (n=77) 
Withdrawn consent from trial (n=5): 
- From trial treatment only (n=1) 
- From trial treatment and follow-up data collection (n=4) 
 
Post-randomisation ineligibility (n=2): 
- Prior therapy for CLL (n=1) 
- Active or prior Hepatitis B or C (n=1) 
 
 Lost to follow-up: missing primary endpoint data (n=8): 
- Missing trephine sample (n=6) 
- Withdrew from follow-up data collection prior to assessment of 
primary endpoint (n=2) 
 
Allocated to FCR (n=100): 
 
Received FCR throughout the trial (n=98) 
Did not receive any FCR (n=2): 
- Clinical decision due to 17p deletion (n=1)  
- Breach of eligibility criteria, prior therapy for CLL (n=1) 
 
Withdrawn consent from trial (n=4): 
- From trial treatment only (n=1) 
- From trial treatment and follow-up data collection (n=2) 
- From follow-up data collection only (n=1) 
Post-randomisation ineligibility (n=0) 
 
Lost to follow-up: missing primary endpoint data: (n=5) 
- Missing trephine sample (n=4) 
- Unable to assess due to insufficient clinical evaluations performed 
at 3 month post-treatment visit (n=1) 
 
Allocated to FCM-miniR (n=100): 
Received FCM-miniR throughout the trial (n=79) 
Commenced FCM-miniR but transferred over to FCR as a result of the 
interim analysis (n=19) 
Did not receive any FCM-miniR (n=2): 
- Received FCR from cycle one as a result of the interim analysis 
(n=2) 
Randomised (n=200) 
27 
 
Table 1 Baseline Characteristics 504 
 
FCR 
(n=100) 
FCM-miniR 
(n=100) 
Total 
(n=200) 
Age (at randomization)    
 63 (63.0%) 62 (62.0%) 125 (62.5%) 
>65 37 (37.0%) 38 (38.0%) 75 (37.5%) 
Mean (s.d.) 61.8 (8.3) 62.6 (8.3) 62.2 (8.3) 
Median (range) 63 (41, 77) 63 (36, 80) 63 (36, 80) 
Sex    
Male 68 (68.0%) 67 (67.0%) 135 (67.5%) 
Female 32 (32.0%) 33 (33.0%) 65 (32.5%) 
Binet Stage    
Progressive A 20 (20.0%) 14 (14.0%) 34 (17.0%) 
B 41 (41.0%) 54 (54.0%) 95 (47.5%) 
C 39 (39.0%) 32 (32.0%) 71 (35.5%) 
B-symptoms    
Yes 46 (46.0%) 57 (57.0%) 103 (51.5%) 
No 54 (54.0%) 43 (43.0%) 97 (48.5%) 
WHO performance status    
0 55 (55.0%) 61 (61.0%) 116 (58.0%) 
1 40 (40.0%) 37 (37.0%) 77 (38.5%) 
2 5 (5.0%) 2 (2.0%) 7 (3.5%) 
Beta-2 microglobulin concentration 
(mg/L)    
<4 mg/L 37 (37.0%) 35 (35.0%) 72 (36.0%) 
PJ/ 53 (53.0%) 62 (62.0%) 115 (57.5%) 
Missing 10 (10.0%) 3 (3.0%) 13 (6.5%) 
Creatinine clearance (mls/min)    
30-60mls/min 17 (17.0%) 14 (14.0%) 31 (15.5%) 
>60mls/min 83 (83.0%) 86 (86.0%) 169 (84.5%) 
17p deletion    
Yes (poorer risk) 4 (4.0%) 3 (3.0%) 7 (3.5%) 
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FCR 
(n=100) 
FCM-miniR 
(n=100) 
Total 
(n=200) 
No (standard risk) 88 (88.0%) 88 (88.0%) 176 (88.0%) 
Missing 8 (8.0%) 9 (9.0%) 17 (8.5%) 
11q deletion    
Yes (poorer risk) 10 (10.0%) 20 (20.0%) 30 (15.0%) 
No (standard risk) 83 (83.0%) 75 (75.0%) 158 (79.0%) 
Missing 7 (7.0%) 5 (5.0%) 12 (6.0%) 
VH mutational risk status    
VH unmutated or VH3-21 (poorer risk) 52 (52.0%) 52 (52.0%) 104 (52.0%) 
VH mutated and not VH3-21 (standard risk) 30 (30.0%) 31 (31.0%) 61 (30.5%) 
Missing 18 (18.0%) 17 (17.0%) 35 (17.5%) 
 505 
WHO: World Health Organisation 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
 520 
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Table 2 Treatment Summaries 521 
 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-
miniR/FCR 
(n=21) 
Total 
(n=200) 
Discontinued treatment 
prematurely (received 
<6 cycles)? 
    
Yes 30 (30.0%) 28 (35.4%) 1 (4.8%) 59 (29.5%) 
No 70 (70.0%) 51 (64.5%) 20 (95.2%) 141 (70.5%) 
Treatment cycles 
received     
F\FOHV 15 (15.0%) 16 (20.3%) 0 (0.0%) 31 (15.5%) 
> 3 cycles 85 (85.0%) 63 (79.7%) 21 (100.0%) 169 (84.5%) 
Received G-CSF 
during treatment 
(cycles 2 - 6)? 
    
Yes 42 (42.0%) 40 (50.6%) 12 (57.1%) 94 (47.0%) 
No 53 (53.0%) 34 (43.0%) 9 (42.9%) 96 (48.0%) 
Unknown 5 (5.0%) 5 (6.3%) 0 (0.0%) 10 (5.0%) 
 522 
G-CSF: Granulocyte-colony stimulating factor was given if there was significant neutropenia on 523 
a previous cycle of treatment 524 
 525 
 526 
 527 
 528 
 529 
 530 
 531 
 532 
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Table 3 Efficacy Summaries  533 
 534 
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MRD NEGATIVITY 
MRD status 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-
miniR/FCR 
(n=21) 
Total 
(n=200) 
MRD negative 45 (45.0%) 29 (36.7%) 11 (52.4%) 85 (42.5%) 
MRD positive 38 (38.0%) 37 (46.8%) 9 (42.9%) 84 (42.0%) 
Missing 17 (17.0%) 13 (16.5%) 1 (4.8%) 31 (15.5%) 
MRD status 
FCR 
(n=83) 
FCM-miniR 
(n=66) 
Total 
(n=149) 
Difference in MRD-
negative rates & 95% 
CIs 
(FCM-miniR - FCR) 
MRD negative 45 (54.2%) 29 (43.9%) 74 (49.7%) -10.3% (-26.3%, 5.8%) 
MRD positive 38 (45.8%) 37 (56.1%) 75 (50.3%)  
Logistic regression analysis for the % of participants achieving MRD-negativity 
Parameter* Parameter 
estimate SE OR 95% CIs for OR 
FCM-miniR vs. FCR -0.44 0.34 0.65 (0.33, 1.26) 
COMPLETE RESPONSE 
CR status (prior to 
imputation using 
MRD) 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-
miniR/FCR 
(n=21) 
Total 
(n=200) 
Achieved a CR 68 (68.0%) 39 (49.4%) 17 (81.0%) 124 (62.0%) 
Did not achieve a 
CR 18 (18.0%) 28 (35.4%) 3 (14.3%) 49 (24.5%) 
Missing 14 (14.0%) 12 (15.2%) 1 (4.8%) 27 (13.5%) 
CR status (post 
imputation using 
MRD) 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-
miniR/FCR 
(n=21) 
Total 
(n=200) 
Achieved a CR 70 (70.0%) 41 (51.9%) 17 (81.0%) 128 (64.0%) 
Did not achieve a 
CR 22 (22.0%) 34 (43.0%) 3 (14.3%) 59 (29.5%) 
Missing 8 (8.0%) 4 (5.1%) 1 (4.8%) 13 (6.5%) 
CR status (post 
imputation using 
MRD) 
FCR 
(n=92) 
FCM-miniR 
(n=75) 
Total 
(n=167) 
Difference in CR rates 
& 95% CIs 
(FCM-miniR - FCR) 
Achieved a CR 70 (76.1%) 41 (54.7%) 111 (66.5%) -21.4% (-35.8%, -7.0%) 
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Did not achieve a 
CR 22 (23.9%) 34 (45.3%) 56 (33.5%)  
PRIMARY ENDPOINT ANALYSIS  
Logistic regression analysis for the % of participants achieving a CR 
Parameter* Parameter 
estimate SE OR 95% CIs for OR 
FCM-miniR vs. FCR -0.98 0.34 0.37 (0.19, 0.73) 
 535 
CR: Complete remission (CR/CRi) 536 
MRD: Minimal Residual Disease 537 
SE: Standard error  538 
OR: Odds ratio 539 
*Adjusted estimate of the treatment effect from the multivariable logistic regression model, 540 
adjusted for the minimization factors 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
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Table 4 Cost-Effectiveness Results (NHS and PSS perspective) 556 
Strategy 
Total 
Cost 
(sd) 
Total 
QALY 
(sd) 
Inc. 
Cost 
(sd) 
Inc. 
QALY 
(sd) 
ICER 
INB 
(QALYs)  
(sd) 
Within-trial analysis (24-month horizon)* 
FCR 
£17 241 
(745) 
1.610 
(0.04)     
FCM- miniR 
£10 622 
(758) 
1.551 
(0.05) 
-£6 619 
(1,061) 
-0.059 
(0.06) 
£112 193** 
0.27  
(0.08) 
Decision model analysis (Lifetime horizon)* 
FCR 
£31 314 
(7 237) 
7.76 
(0.26)     
FCM- miniR 
£23 590 
(6 997) 
7.04 
(0.36) 
-£7 723 
(3 281) 
-0.73 
(0.42) 
£10 651** 
-0.34 
 (0.40) 
 557 
*For the cost in dollars ($), use an exchange rate of 1:1.43 558 
**Pounds saved per QALY lost 559 
NHS: National Health Service 560 
PSS: Personal and Social Services 561 
QALY: Quality-Adjusted Life-Years 562 
ICER: Incremental Cost-Effectiveness Ratio 563 
INB: Incremental Net Benefit 564 
  565 
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Table 5 Safety and Toxicity Summaries 566 
 
FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-
miniR/FCR 
(n=19) 
Total 
(n=198) 
Serious Adverse Events (SAEs) 
Number of 
participants 
experiencing an 
SAE 
49 (49.0%) 46 (58.2%) 9 (47.4%) 104 (52.5%) 
Total number of 
SAEs reported 80 81 22 183 
Number of 
participants 
requiring 
hospitalization for 
an SAE 
46 (46.0%) 41 (51.9%) 9 (47.4%) 96 (48.5%) 
Serious Adverse Reactions (SARs) 
Number of 
participants 
experiencing a SAR 
41 (41.0%) 39 (49.4%) 9 (47.4%) 89 (44.9%) 
Total number of 
SARs reported 62 67 16 145 
SARs by MedDRA 
System Organ 
Class* 
    
Blood and lymphatic 
system disorders 8 (12.9%) 8 (11.9%) 0 (0.0%) 16 (11.0%) 
Gastrointestinal 
disorders 4 (6.5%) 4 (6.0%) 2 (12.5%) 10 (6.9%) 
General disorders 
and administration 
site conditions 
10 (16.1%) 6 (9.0%) 3 (18.8%) 19 (13.1%) 
Immune system 
disorders 0 (0.0%) 1 (1.5%) 0 (0.0%) 1 (0.7%) 
Infections and 
infestations 36 (58.1%) 43 (64.2%) 11 (68.8%) 90 (62.1%) 
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FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-
miniR/FCR 
(n=19) 
Total 
(n=198) 
Musculoskeletal and 
connective tissue 
disorders 
0 (0.0%) 1 (1.5%) 0 (0.0%) 1 (0.7%) 
Neoplasms benign, 
malignant and 
unspecified 
(including cysts and 
polyps) 
1 (1.6%) 1 (1.5%) 0 (0.0%) 2 (1.4%) 
Psychiatric disorders 1 (1.6%) 0 (0.0%) 0 (0.0%) 1 (0.7%) 
Renal and urinary 
disorders 0 (0.0%) 2 (3.0%) 0 (0.0%) 2 (1.4%) 
Skin and 
subcutaneous tissue 
disorders 
2 (3.2%) 1 (1.5%) 0 (0.0%) 3 (2.1%) 
Adverse Events (AEs) 
Number of 
participants 
experiencing an AE 
96 (96.0%) 77 (97.5%) 19 (100%) 192 (97.0%) 
Total number of 
AEs reported 1117 863 183 2163 
CTCAE grade     
<3 943 (84.4%) 667 (77.3%) 156 (85.2%) 1766 (81.6%) 
 168 (15.0%) 193 (22.4%) 27 (14.8%) 388 (17.9%) 
Missing 6 (0.5%) 3 (0.3%) 0 (0.0%) 9 (0.4%) 
Secondary Cancers 
Number of 
participants 
reporting each 
secondary cancer 
    
Hematological 
(Lymphoma) 2 (2.0%) 2 (2.5%) 0 (0.0%) 4 (2.0%) 
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FCR 
(n=100) 
FCM-miniR 
(n=79) 
FCM-
miniR/FCR 
(n=19) 
Total 
(n=198) 
Hematological 
(AML/MDS) 3 (3.0%) 3 (3.8%) 0 (0.0%) 6 (3.0%) 
Skin (Non-
melanoma) 4 (4.0%) 5 (6.3%) 1 (5.3%) 10 (5.1%) 
Skin (Melanoma) 2 (2.0%) 1 (1.3%) 0 (0.0%) 3 (1.5%) 
Non-hematological 
(Solid tumors) 4 (4.0%) 1 (1.3%) 0 (0.0%) 5 (2.5%) 
 567 
*Percentages are out of total number of SARs reported 568 
MedDRA: Medical Dictionary for Regulatory Activities 569 
CTCAE: Common Terminology Criteria for Adverse Events 570 
AML: Acute myeloid leukemia 571 
MDS: Myelodysplastic syndrome 572 
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Figure 2 Kaplan Meier Curves for Progression-Free and Overall Survival 584 
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Figure 3 Kaplan Meier Curves for Subgroup Analyses for Progression-Free Survival  587 
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